一种雄性激素受体抑制剂的结晶形式及其制备方法技术

提供了一种雄性激素受体抑制剂的结晶形式及其制备方法。具体地，提供了(S)‑4‑(3‑(4‑(2，3‑二羟基丙氧基)苯基)‑4，4‑二甲基‑5‑羰基‑2‑硫代咪唑啉‑1‑基)‑2‑(三氟甲基)苯甲腈(式(I)化合物)的I型结晶及其制备方法，所述方法包括：1)将任意晶型或无定型的式(I)所示化合物加入适量的有机溶剂中，加热溶清后冷却析晶，所述有机溶剂选自碳原子数小于等于5的酯类、酮类、腈类、醚类的任意一种或它们的混合溶剂；2)过滤结晶并洗涤，干燥。所得式(I)化合物的I型结晶具备良好的化学稳定性和晶型稳定性，并且所用结晶溶剂低毒低残留，可更好地用于临床治疗。

Crystalline form of androgen receptor inhibitor and method for preparing the same

A crystalline form of a androgen receptor inhibitor and a process for its preparation are provided. Specifically, provides (S) 4 (3 (4 (2, 3 two hydroxy propoxy) phenyl) 4, 4 two methyl 5 carbonyl 2 thio 1 imidazoline based (three) 2 trifluoromethyl benzonitrile (type) (I) compound) type I crystal and a preparation method thereof. The method comprises the following steps: 1) any crystalline or amorphous type (I) compound adding proper amount of organic solvent, heating the solution clear after cooling crystallization, the organic solvent is selected from the number of carbon atoms is less than or equal to 5 of any ketones, esters, nitriles, ethers or a mixed solvent; 2) crystallization and filtration and washing, drying. I (I) compounds have good chemical stability and crystalline stability, and their crystalline solvents are low toxic and low residue, which can be better used in clinical treatment.

【技术实现步骤摘要】
【国外来华专利技术】PCT国内申请，说明书已公开。

【技术保护点】
PCT国内申请，权利要求书已公开。

【技术特征摘要】
【国外来华专利技术】2015.09....

【专利技术属性】
技术研发人员：武乖利，郭昌山，钟良，卢韵，
申请(专利权)人：江苏恒瑞医药股份有限公司，
类型：发明
国别省市：江苏,32